Why is this education important?
Pharmacists are involved in all phases of a patient’s cancer journey and their role continues to expand in response to the rapid pace of therapeutic advances. This evolving role is especially critical in the complex treatment of patients with HR+/HER2- metastatic breast cancer. Availability of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors has shifted the treatment paradigm but identification of which patients may benefit from particular CDK4/6 inhibitors must consider a patient’s ability to tolerate adverse events related to the treatments and continue therapy.
- Individualize therapy with CDK4/6 inhibitors for patients with HR+/HER2- breast cancer?
- Monitor and manage adverse events associated with CDK4/6 inhibitors?
- Apply and integrate physician-pharmacist collaborative management strategies in your practice setting?
- Establish pharmacist-led patient management initiatives?
Is your team equipped to:
Working collaboratively with expert educators, your team will participate in formative evaluation and action planning to identify and model change elements to improve future practices and processes.
Establish frameworks for physician-pharmacist collaborative strategies to improve monitoring and management of adverse events, support personalized care for patients with HR+/HER2- metastatic breast cancer, and improve patient outcomes.
Support professional development! Identify a team member to participate in our training and then facilitate the program at your site to mitigate inefficiencies or deficiencies that currently exist.
Choose topics that are most relevant to your setting to customize a presentation to improve the quality of care for patients and develop collaborative frameworks that will work for you and your team. Embrace the evolving role of pharmacists in patient care today!
How does this initiative support you?
Purdue University College of Pharmacy and the Academy for Continued Healthcare Learning (ACHL) partnered on this initiative to support your efforts to improve your team’s knowledge of medically integrated pharmacies and the role of pharmacists in monitoring and managing adverse events, improving treatment adherence, and facilitating patient education around treatment with CDK4/6 inhibitors in HR+/HER2- breast cancer. You can access experts to deliver high-level education efficiently and cost-effectively.
Educators are trained to deliver targeted programs while applying adult learning principles to foster engagement, promote critical thinking, and drive acquisition of enhanced clinical competency. Your team receives access to the latest data and critical real-world perspectives and guidance for translating the data to practice.
Learners will improve their ability to adopt best practices of medically integrated pharmacies to enhance patient care.
What can I expect when scheduling my program?
Access our directory to share your contact details; date and time preferences; topics and program length; and number of attendees. You’ll have the opportunity to select up to 3 preferred educators, each of whom is prepared to develop a program customized to meet the needs of your team and the diverse patients you manage.
FAQs
- Review examples of medically integrated pharmacies (MIP) and discuss possible benefits to expanding clinical services for monitoring and managing AEs in patients treated with oral anticancer therapies.
- Implement pharmacy-led strategies to proactively monitor and mitigate CDK4/6 inhibitor-associated AEs to improve patient adherence and clinical outcomes in breast cancer patients.
- Create pharmacy-driven coordination of care protocols to enhance patient education and facilitate feedback collection and interpretation.